TCR2 THERAPEUTICS INC. Annual Share-based Payment Arrangement, Expense in USD from 2018 to 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Tcr2 Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2018 to 2022.
  • Tcr2 Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2023 was $579K, a 81.8% decline year-over-year.
  • Tcr2 Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2023 was $8.78M, a 28.7% decline year-over-year.
  • Tcr2 Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $11.4M, a 7.22% decline from 2021.
  • Tcr2 Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $12.3M, a 44.4% increase from 2020.
  • Tcr2 Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2020 was $8.49M, a 26.7% increase from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $11.4M -$885K -7.22% Jan 1, 2022 Dec 31, 2022 10-K 2023-03-23
2021 $12.3M +$3.77M +44.4% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-23
2020 $8.49M +$1.79M +26.7% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-22
2019 $6.7M +$4.57M +214% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-16
2018 $2.13M Jan 1, 2018 Dec 31, 2018 10-K 2020-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.